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Background: Spermatic cord torsion can lead to testis ischemia (I) and subsequent ischemia-reperfusion (I/R)
causing germ cell-specific apoptosis. Previously, we demonstrated that the hypoxia-inducible factor-1 (HIF-1)
transcription factor, a key regulator of physiological responses to hypoxia, is abundant in Leydig cells in normoxic
and ischemic testes. We hypothesize that testicular HIF-1 activates the expression of antiapoptotic target genes to
protect Leydig cells from apoptosis. In silico analysis of testis genes containing a consensus hypoxia response
element (HRE, 5’-RCGTG-3’) identified myeloid cell leukemia-1 (Mcl-1) as a potential HIF-1 target gene. The purpose
of this study was to determine whether HIF-1 shows DNA-binding activity in normoxic and ischemic testes and
whether Mcl-1 is a target gene of testicular HIF-1.
Methods: The testicular HIF-1 DNA-binding capacity was analyzed in vitro using a quantitative enzyme-linked
immunosorbent assay (ELISA) and electrophoretic mobility shift assays (EMSA). MCL-1 protein expression was
evaluated by immunoblot analysis and immunohistochemistry. The binding of testicular HIF-1 to the Mcl-1 gene
was examined via chromatin immunoprecipitation (ChIP) analysis.
Results: The ELISA and EMSA assays demonstrated that testicular HIF-1 from normoxic and ischemic testes binds
DNA equally strongly, suggesting physiological roles for HIF-1 in the normoxic testis, unlike most tissues in which
HIF-1 is degraded under normoxic conditions and is only activated by hypoxia. MCL-1 protein was determined to
be abundant in both normoxic and ischemic testes and expressed in Leydig cells. In a pattern identical to that of
HIF-1 expression, the steady-state levels of MCL-1 were not significantly affected by I or I/R and MCL-1 co-localized
with HIF-1α in Leydig cells. Chromatin immunoprecipitation (ChIP) analysis using a HIF-1 antibody revealed
sequences enriched for the Mcl-1 promoter.
Conclusions: The results demonstrated that, unlike what is observed in most tissues, HIF-1 displays DNA-binding
activity in both normoxic and ischemic testes, and Mcl-1 may be a key target gene of testicular HIF-1 with potential
roles in the antiapoptotic protection of Leydig cells.
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Hypoxia-inducible factor-1 (HIF-1), often described as a
“master” regulator of hypoxic responses in mammalian
cells, is a well-characterized transcription factor known
to activate over 100 different hypoxia-sensitive genes
involved in a range of metabolic processes including
anti- and proapoptotic responses to ischemia and hyp-
oxia [1,2]. Thus, HIF-1 has been widely studied due to
its implication in a range of disease conditions and is-
chemic processes of clinical importance [3,4].
We are interested in studying HIF in the testis in part
because clinical conditions such as testicular torsion
(spermatic cord torsion), varicocoele and hypobaric hyp-
oxia can cause hypoxic and ischemic injury of the testis
[5-7]. Germ cell-specific apoptosis [8], activation of in-
flammatory pathways [9], lipid peroxidation [7] and
alterations in testis protein profiles [10] are among the
many effects of hypoxia on the testis that have been
widely-studied, although Leydig cells and Sertoli cells
appear to be generally resistant to ischemia and hypoxia-
induced apoptosis [8].
HIF-1 can have antiapoptotic or apoptotic effects on
cells depending on the extent and duration of the oxy-
gen debt [11]. We hypothesize that HIF-1 plays import-
ant roles in mediating antiapoptotic responses in the
testis and may protect Leydig cells from apoptosis. Pre-
viously we demonstrated that HIF-1α mRNA and pro-
tein is abundantly expressed by Leydig cells in the rat
testis [12,13]. These studies revealed that, unlike many
tissues in which HIF-1α expression is induced by hyp-
oxia, HIF-1 is constitutively expressed in the normoxic
testis and the levels of testicular HIF-1 are unaffected
following ischemia and hypoxia caused by testicular tor-
sion and reperfusion [12]. HIF-1α is also expressed in
Leydig cells in the normoxic mouse testis [14].
A body of work is emerging that demonstrates that
HIF-1α may be functionally active in normoxic tissues
[15]. Measurements of the physiological oxygen tension
in the testis indicate that testicular pO2 levels are likely
low, bordering on hypoxia [16-18] and it has been sug-
gested that other factors such as reactive oxygen species
render the testis hypoxic even under presumptive nor-
moxic conditions. If the testis is indeed a hypoxic tissue,
then this may explain the constitutive expression of
HIF-1 in the testis. However, little is known about HIF-1
target genes in the testis, and this area of research is of
interest to investigators seeking to understand the cellu-
lar and molecular responses of Leydig cells to changes in
the oxygen microenvironments in the testis. Lysiak et al.
showed that in the mouse testis, HIF-1α regulates the
expression of the 3β-hydroxysteroid dehydrogenase type
I (Hsd3b1) gene [14].
In the present study, we wanted to determine if tes-
ticular HIF-1 is active and capable of binding DNAunder normoxic and hypoxic conditions. Additionally,
we propose that another possible target for testicular
HIF-1 is the myeloid cell leukemia-1 (Mcl-1) gene, an
antiapoptotic member of the Bcl-2 family, which was
first discovered in the human ML-1 myeloid leukemia
cell line [19]. We used in vitro DNA-binding assays
(ELISA and EMSA) to demonstrate that testicular HIF-1
from normoxic and ischemic testes displays DNA-
binding activity. When we examined the expression of
Mcl-1 as a potential antiapoptotic target gene of testicu-
lar HIF-1, MCL-1 protein was determined to be abun-
dant in Leydig cells in both normoxic and ischemic
testes. ChiP analysis using an HIF-1 antibody revealed
sequences enriched for Mcl-1 promoter, providing evi-
dence for Mcl-1 as a key target gene of testicular HIF-1
with potential roles in antiapoptotic protection of Leydig
cells.
Methods
Animals and surgical procedures
Adult male, retired-breeder Sprague–Dawley rats (550–
650 g) purchased from Charles River Laboratories (Stone
Ridge, NY) were housed under controlled conditions of
temperature and humidity on a twelve-hour light/dark
cycle. Animal care and surgical procedures were carried
out following guidelines established by the National
Institutes of Health (NIH) Public Health Service Policy
and the Monmouth University Institutional Animal Care
and Use Committee (IACUC).
Animals were anesthetized using injections of sodium
pentobarbital (Sigma-Aldrich, St. Louis, MO) at a con-
centration of 75 mg of pentobarbital per kg of body
weight. Torsion surgeries were performed via a midline
laparotomy using sterile procedures and with animals
maintained on warming pads to prevent hypothermia as
previously described [8,13]. Torsion was induced unilat-
erally to create an experimental state of ischemia. Fol-
lowing an abdominal incision, the gubernaculum was
cut and the testis and epididymis were exposed through
the laparatomy incision. The connective tissue holding
the testis to the epididymis was separated and the testis
rotated 720° clockwise. Then, the testis and epididymis
were returned to the scrotum, the laparatomy incision
closed and the testis maintained in torsion. In reperfu-
sion experiments, each torsed testis was detorsed and
the testicular and scrotal stumps of the divided guberna-
culum were sutured together to hold the testis in place
for the duration of the reperfuson treatment phase and
the testis and epididymis were returned to the scrotum.
Contralateral, sham-treated testes served as controls.
The surgeries were carried out on alternating sides so
that sham or ischemia induction was performed in right
and left testes for all time points. Each animal had a
sham testis and an ischemic testis. Animals were
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gical treatment.
The treatment groups involved the following condi-
tions (n = 3–6 animals/group): 1 hour or 6 hours of
ischemia (I), or 1 hour of ischemia followed by 4 hours
of reperfusion (1h/4h I/R). At the conclusion of the
treatment, euthanasia was performed via carbon dioxide
asphyxiation in accordance with the Report of the
American Veterinary Medical Association (AVMA)
Panel on Euthanasia (2000). The testes were excised,
then frozen in liquid nitrogen and stored at −70°C prior
to RNA or protein isolation. Apoptosis of germ cells in
the testes following I and I/R was evaluated via terminal
deoxynucleotidyltransferase mediated dUTP-biotin nick
end labelling (TUNEL) assays to validate cell damage.
These data were previously reported in Supplemental
Data of Palladino et al. [12] and demonstrated an in-
crease in germ cell-specific apoptosis following I and
I/R, but no statistically significant changes in apoptosis
of Leydig cells after I and I/R.
Isolation of cytoplasmic and nuclear proteins
Fresh or frozen tissue samples were placed on ice and
homogenized in 3 volumes of lysis buffer composed of
10 mM Tris–HCl (pH 7.5), 1.5 mM MgCl2, and 10 mM
KCl with freshly added 1 mM dithiothreitol (DTT), 1
mM Na3VO4, and 10 mM protease inhibitor mix
(P8340; Sigma-Aldrich, St. Louis, MO). The homogenate
was centrifuged at 3,500 rpm at 4°C for 5 minutes and
the resulting supernatant was saved as the cytoplasmic
fraction and stored at −80°C. To isolate nuclear pro-
teins, the pellet obtained from the initial centrifugation
step was resuspended in 0.42 M KCl, 20 mM Tris–HCl
(pH 7.5), 1.5 mM MgCl2, and 20% glycerol, with freshly
added 1 mM dithiothreitol (DTT), 1 mM Na3VO4, and
protease inhibitor cocktail (P8340; Sigma-Aldrich),
mixed at 150 rpm at 4°C for 30 minutes to liberate pro-
teins from nuclei and then centrifuged at 13,500 rpm
for 30 minutes at 4°C. The resulting supernatant con-
taining nuclear proteins was removed and stored at
−80°C. Protein concentrations were determined via the
Bradford assay (Bio-Rad, Hercules, CA).
Enzyme-linked immunosorbent assay (ELISA) to detect
HIF-1 DNA binding
Testicular HIF-1 DNA binding was determined using
the Active Motif TransAM™ HIF-1 Transcription Factor
Assay Kit (Active Motif, Carlsbad, CA) following the
manufacturer’s instructions. In this assay, wells are pre-
coated with oligonucleotides containing the consensus
hypoxia response element (HRE: 5’-TACGTGCT-3’, con-
sensus sequence for the HRE underlined) from the
human EPO gene and HIF-1 DNA binding of protein
extracts is determined by incubating 10 μg aliquots ofnuclear proteins in the wells for 1 hour at room
temperature. Protein extracts from CoCl2-treated hyp-
oxic COS-7 cells (Active Motif ) were used as positive
controls for HIF-1 binding. After several washing steps,
100 μl of a goat anti-HIF-1α primary antibody (AF1935;
R&D Systems, Inc., Minneapolis, MN) was added, fol-
lowed by incubation for 1 hour at room temperature
and detection with an anti-IgG-horseradish peroxidase
(HRP)-conjugated secondary antibody. Colorimetric
changes were determined via spectrophotometric meas-
urement of the absorbance at 450 nm, with a reference
reading obtained at 655 nm and a background calcula-
tion deducted from each well. The absorbance readings
were quantitated as a fold increase of the negative con-
trol. Samples were run in triplicate using protein
extracts isolated from testes treated for different times
under I or I/R (n = 3–6 animals for each treatment
group) and the statistical significance of results was
determined via Analysis of Variance (ANOVA).
Electrophoretic mobility shift assays (EMSA)
Electrophoretic mobility shift assays were performed
using the Thermo Scientific LightShiftW Chemilumines-
cent EMSA kit according to the manufacturer’s instruc-
tions (Thermo Scientific, Rockford, IL). The reactions
were carried out in 20 μl volumes with 5 μg of a nuclear
or cytoplasmic protein extract from the testis incubated
with 10× binding buffer, 1 μg/μl poly (dI•dC), 50% gly-
cerol, 1% NP-40, 1M KCl, 100 mM MgCl2, and 200 mM
EDTA and biotin-labelled EMSA oligonucleotides for 20
minutes at room temperature. Epstein-Barr Nuclear
Antigen (EBNA) and biotin-labelled double-stranded
target DNA was included as a positive control for the
EMSA. A double-stranded HIF-1 oligonucleotide con-
taining the consensus HRE (5’-TCTGTACGTGACC
ACACTCACCTC-3’, consensus sequence for the HRE
underlined; sc-2625, Santa Cruz Biotechnology, Santa
Cruz, CA) and mutant oligonucleotides (sc-2626; Santa
Cruz Biotechnology) with an AAA substitution in place
of the CGT in the consensus site were used for EMSA.
Terminal deoxynucleotidyl transferase (TdT) was
employed to catalyze the biotin labelling of the oligonu-
cleotides used for EMSA according to the manufac-
turer’s instructions (Pierce Biotin 3’ End DNA Labelling
Kit). Labelling reactions with a 50 μl volume containing
the appropriate oligonucleotides were incubated for 30
minutes at 37°C in ultrapure water, 5X TdT Reaction
Buffer, Biotin-11 UTP, and diluted TdT. To stop each re-
action, 0.2 M EDTA was added and 24:1 chloroform:
isoamyl alcohol extraction performed to remove protein
from labelled oligonucleotide. Labelled oligonucleotides
were stored at −20°C.
The EMSA reactions were separated using 6% poly-
acrylamide TBE PAGErW Gold gels (Lonza, Rockland,
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buffer (Lonza AccuGENEW 10× TBE Buffer). Binding
reactions were transferred onto nylon membrane
(Thermo Scientific BiodyneW B) which were then cross-
linked at 120 mJ/cm2 for 60 seconds using a UV-light
cross-linker instrument. The blots were blocked with
blocking buffer, incubated with a 1:300 dilution of a sta-
bilized streptavidin-HRP conjugate for 15 minutes at
room temperature and then reacted with luminal/enhan-
cer solution (Pierce Chemiluminescent Nucleic Acid De-
tection Module). The blots were exposed to x-ray film
(BioMax ML; Kodak, Rochester, NY) for 2–5 minutes, or
digital images were captured using a ChemiDoc™ XRS+
Molecular Imager with Image Lab™ Software (Bio-Rad).
For competition experiments, an excess of the un-
labeled HIF-1α consensus oligonucleotide was used to
demonstrate competition for DNA binding between
biotin-labelled and unlabeled oligonucleotides. In super-
shift experiments, the specificity of HIF-1 DNA binding
was demonstrated on 4-20% polyacrylamide TBE
PAGErW Gold gels which were electrophoresed in 0.5×
Tris-borate-EDTA (Lonza). Goat anti-human polyclonal
antibodies C-19 and Y-15 (sc-8711 and sc-12542 respec-
tively; Santa Cruz Biotechnology) were used to perform
supershift experiments. All EMSA experiments were
replicated a minimum of 5 times with independent sam-
ples (n=3-6 animals for each treatment group). Repre-
sentative results are presented.
Immunoblot analysis
Immunoblot analysis was performed following denatur-
ing sodium dodecyl sulfate (SDS) polyacrylamide gel
electrophoresis (PAGE) of nuclear and cytoplasmic sam-
ples in 7.5% or 10% PAGErW Gold Tris-Glycine poly-
acrylamide gels (Lonza, Rockland, ME). Tissue extracts
obtained from COS-7 cells (Active Motif, Carlsbad, CA),
rat PC-12 pheochromocytoma (Active Motif ), and the
BJAB human B cell lymphoma line (Santa Cruz Biotech-
nology, Santa Cruz, CA) were included as positive con-
trols for detecting HIF-1. Seventy-five microgram
aliquots of protein samples were heated for 5 minutes at
95°C prior to loading and then electrophoresed at 150 V
for approximately 90 minutes. Proteins were electro-
blotted onto Trans-Blot nitrocellulose membranes (Bio-
Rad), and Ponceau S staining (0.0005% in 1% acetic acid)
was used to confirm protein transfer. The blots were
blocked in 1× Western Wash (50 mM Tris, pH 7.6,
30 mM NaCl, 0.001% Tween 20) containing 5% nonfat
dry milk under gentle agitation at room temperature for
30 minutes. For the detection of MCL-1, the blots were
incubated overnight with gentle agitation at 4°C in a
1:1,000 dilution of an Mcl-1 primary antibody (rabbit
polyclonal IgG;C. sc819, Santa Cruz Biotechnology) in
1× Western Wash and 5% nonfat dry milk.After 3 washes with 1× Western Wash, the blots were
incubated with an HRP-conjugated secondary antibody
(goat anti-rabbit IgG; sc2054) at a 1:20,000 dilution in
1× Western Wash with 5% nonfat dry milk for 1 hour at
room temperature under gentle agitation. Following 3
washes with 1×7 Western Wash, the blots were devel-
oped via enhanced chemiluminescence in SuperSignal
West Pico or Femto substrate (Pierce, Rockford, IL) and
exposed to X-ray film (Biomax ML).
The blots were stripped of bound antibody by incuba-
tion in Restore Buffer (Pierce) at 37°C for 15 minutes
and then washed in 1× Western Wash for 5 minutes,
prior to blocking and reprobing. The blots were probed
for activating transcription factor-2 (ATF-2) using a
1:1,000 dilution of an anti-ATF-2 antibody (rabbit poly-
clonal IgG; sc-6233) to detect ATF-2 as a hypoxia-
independent loading control for protein quantification.
Negative control experiments to determine antibody
specificity were carried out by incubating the blots with
pre-immune sera, followed by incubation with secondary
antibodies. Mcl-1 protein levels were normalized to
ATF-2 as a loading control. Immunoblot data were ana-
lyzed by one-way ANOVA and the results considered
significantly different at P< 0.05.
Immunoblot analysis was conducted to determine the
presence of MCL-1 in cultured Leydig cells. Cultured
cells were provided by the Hardy lab of the Population
Council at the Center for Biomedical Research (New
York, NY). Briefly, Leydig cells were purified from 325
to 350 g Sprague–Dawley rats using a previously
described collagenase dispersal and sedimentation ap-
proach [20]. Typically, 6 animals were required to yield
10 to 20 million adult Leydig cells. A hemocytometer
was used to estimate cell yields and the percentage of
purity was assessed via histochemical staining to detect
3β-hydroxysteroid dehydrogenase with etiocholan-3β-
ol-17-one as the enzyme substrate. The adult Leydig
cell preparations used for these experiments were over
95% pure. Equal number of cells were allocated to T-25
flasks and cultured in buffered Dulbecco’s modified
Eagle’s medium: F12 culture medium supplemented
with ovine luteinizing hormone (0.1 ng/mL) and lipo-
proteins (Lipimate; Hyclone Logan, Utah). Fresh isolates
of cells were used for isolating MCL protein, or cells
were cultured at 34° C for 20 hours in an incubator
containing either a 5% O2/5% CO2 atmosphere or a
21% O2/5% CO2 atmosphere. Five separate replicates
were performed for each of the culture conditions in
these experiments. Leydig cells were collected from
the flasks using trypsin, centrifuged and frozen in li-
quid nitrogen as cell pellets for subsequent MCL pro-
tein isolation.The applied oxygen concentrations were
chosen to mimic hypoxic and normoxic conditions,
respectively.
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10% Tris-glycine polyacrylamide gels via SDS-PAGE and
immunoprobing procedures were carried out as described
above. The immunoblots were run with the total protein
aliquots isolated from equivalent numbers of cells (1 mil-
lion cells) for each treatment group.
Immunocytochemistry (IHC)
To determine which cell types in the testis express Mcl-
1, tissue sections were prepared for immunocytochem-
istry. Tissues were placed in 10% (w/v) neutral-buffered
formalin (Richard-Allan Scientific, Kalamazoo, MI) over-
night prior to paraffin embedding. The tissue samples
were then dehydrated in three successive changes of 70%,
95% and 100% ethanol then transferred through three
changes of xylene and incubated overnight at 60°C in a
1:1 xylene/molten paraffin mixture. Finally, the samples
were incubated at 60°C in fresh molten paraffin for 1 hour
through a total of 3 changes and then embedded in paraf-
fin. Paraffin sections were cut at a thickness of 5 μm and
mounted on glass slides (SuperfrostW Plus; VWR).
The sections were deparaffinized in xylene and
hydrated through a series of graded ethanol solutions
and then rinsed in 1× phosphate-buffered saline (PBS)
solution for 5 minutes to complete the hydration steps.
Then, the slides were covered in antigen unmasking solu-
tion (Vector Laboratories, Inc., Burlingame, CA), micro-
waved on high for 10 minutes and cooled for 1 hour at
room temperature. The slides were next rinsed in 1× PBS
for 5 minutes and quenched in 0.5% (v/v) H2O2/metha-
nol for 30 minutes, then washed in 1× PBS for 5 minutes,
placed into a humidified chamber, and incubated with
blocking serum for 20 minutes using serum from the
species of origin of the secondary antibody. A 1:100 dilu-
tion of an Mcl-1 primary antibody (rabbit polyclonal IgG;
sc819) in 1× PBS was added to the testis samples as well
as slides containing sections of spleen as a positive con-
trol, and the slides incubated in a humidified chamber
overnight at 4°C. Negative control sections were incu-
bated in the absence of primary antibody.
The slides were washed in 1× PBS for 5 minutes with
a total of 3 changes. The slides were then incubated in
biotinylated secondary antibody (goat anti-rabbit IgG;
sc2054) at a 1:200 dilution in 1× PBS combined with
Santa Cruz blocking serum for 45 minutes in a humidi-
fied chamber at room temperature. Next, the slides
were washed in 1× PBS for 5 minutes through a total
of 3 changes and incubated in the Santa Cruz AB
(avidin-biotin) enzyme reagent for 30 minutes at room
temperature. The slides were subsequently washed in 1×
PBS through a total of 3 changes, and sections were
incubated with diaminobenzidine/peroxidase substrate
for 10 minutes at room temperature followed by
washing with dH2O prior to counterstaining withhematoxylin. Finally, the sections were dehydrated in a
graded series of ethanol solutions, placed in xylene, and
cover slips were mounted using Permount (Fisher Scien-
tific, Pittsburgh, PA). The slides were examined under a
Nikon Eclipse 50i light microscope (Nikon Instruments,
Inc., Melville, NY) and photographed using a DS-L1
digital camera.Chromatin immunoprecipitation (ChIP) assays
ChIP assays were carried out with the Active Motif
ChIP-IT™ Express kit as per protocols outlined in the
manufacturer’s instruction manual. In place of cultured
cells, a 0.50 g sample of freshly excised testis from sham
and surgically treated animals was used to isolate chro-
matin complexes. The tissue samples were incubated
in 20 ml of fixation solution (37% formaldehyde; Dulbec-
co’s modified Eagle’s medium) under gentle agitation for
10 minutes at room temperature, then washed with ice-
cold 1× PBS. Fixation was stopped by adding 10 ml of a
glycine-1× PBS stop-fix solution followed by swirling
and rocking at room temperature for 5 minutes. The
samples were washed with 1× ice-cold PBS and cells
were pelleted by centrifugation at 2,500 rpm for 10
minutes at 4°C. Finally, 1 μl of 100 mM phenylmethyl-
sulfonylfluoride (PMSF) and 1 μl protease inhibitor
cocktail (PIC) were added to the cell pellets, which were
then stored at −80°C.
For ChIP assays, the pellets were subsequently thawed
in 1 ml of ice-cold lysis buffer (supplemented with 5 μl
PIC + 5 μl PMSF) and incubated on ice for 30 minutes.
Cell nuclei were released by homogenizing the cell pel-
lets using an ice-cold glass dounce homogenizer fol-
lowed by centrifugation at 5,000 rpm for 10 minutes at
4°C to pellet chromatin. The pellets were resuspended in
1.0 ml of digestion buffer pre-warmed at 37°C and sup-
plemented with 5 μl PIC + 5 μl PMSF.
Chromatin DNA was enzymatically sheared using
DNase (200U/ml) and optimal enzymatic shearing con-
ditions determined by placing 50 μl aliquots of chroma-
tin in digestion buffer that had been pre-warmed at 37°C
for 5 minutes and adding a working stock of an enzym-
atic shearing cocktail to the chromatin, followed by in-
cubation for 5, 10 or 15 minutes. The reactions were
stopped by adding 1 μl of ice-cold 0.5 M EDTA followed
by chilling on ice for 10 minutes. Sheared chromatin
samples were then centrifuged at 10,000 rpm for
10 minutes at 4°C and stored at −80°C. Proteinase K-
treated chromatin samples were electrophoresed
through 1% agarose gels prepared in 1× sodium boric
(SB) acid buffer (Faster Better Media, LLC, Baltimore,
MD) [21] containing SYBRW Safe (Invitrogen) and visua-
lized to determine the size range of the sheared DNA
and optimum shearing conditions.
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HIF-1/chromatin complexes. Briefly reaction tubes were
loaded with Protein G magnetic beads, ChIP Buffer,
sheared chromatin, PIC, and 100 μg of a HIF-1α primary
antibody (AF1935; R&D Systems, Inc., Minneapolis,
MN) diluted in 3 μl of 1× PBS in 100 μl reaction
volumes. Chromatin in positive control samples was
incubated with a primary antibody for RNA polymerase
II (ChIP-IT™ Express Enzymatic, Active Motif ), and
negative control samples were incubated with a nonspe-
cific IgG antibody or polyclonal antibody to β-actin. The
reactions were incubated on a rolling shaker for 4 hours
at 4°C, and the tubes were then placed on a magnetic
stand to pellet the beads on the side of the tube. The
supernatant was discarded and the beads were washed
three times with ChIP buffers and reverse cross-linking
buffer to elute chromatin.
Polymerase chain reaction (PCR) amplification was
employed to identify ChIP-enriched sequences. The PCR
master mix consisted of the following components:
196 μl of diethylpyrocarbonate-treated H2O, 50 μl 10× PCR
buffer, 50 μl 10× loading dye, 20 μl of a dNTP mixture,
4 μl of Taq polymerase, and 80 μl of dH2O (for control
PCR sample only) or 40 μl forward/40 μl reverse primers
(either for β-actin or for Mcl-1). The rat β-actin primer
came from the ChIP-IT™ Control Kit (Active Motif ).
Mcl-1 forward (5’-ACTTGAGGCCATGAGTTCGA
GACCA-5’) and reverse (5’-CTCCACTTCCCACGTT
CAGACGATT-3’) primers were designed based on the
rat Mcl-1 promoter sequence (AF147742.1) spanning the
HRE portion of the promoter and were purchased from
MWG Biotech Inc. (High Point, NC).
Aliquots of chromatin samples were incubated in PCR
mix containing either β-Actin primers or Mcl-1 primers,
and the samples were amplified using the following ther-
mocycling conditions: 36 cycles of 94°C for 20 seconds,
59°C for 30 seconds, and 72°C for 30 seconds. Analysis of
the obtained PCR products was carried out via electro-
phoresis of 8 μl aliquots of each amplified sample on 2%
agarose gels prepared in 1× SB buffer containing SYBRW
Safe. The PCR products were cloned into pGEM-T
Easy plasmid vectors (Promega Corp., Madison, WI) and
sequences of enriched DNA were confirmed by cycle se-
quencing using a LI-COR 4300L DNA sequencer (LI-COR
Biosciences, Lincoln, NE) and BLAST (Basic Local Align-
ment Search Tool analysis (Altschul, et al., 1990).
Results
Testicular HIF-1 from normoxic and ischemic testis
displays DNA-binding activity
We previously demonstrated [12] that unlike many other
tissues in which HIF-1 accumulates only after hypoxia,
HIF-1 is abundant in normoxic testes. This result sug-
gested potentially novel roles for HIF-1 in the testis.Thus, we sought to determine if testicular HIF-1 is cap-
able of DNA binding in the normoxic testis and to de-
termine if HIF-1 DNA binding is affected by the
ischemic conditions that cause testis hypoxia. ELISA and
EMSAs to detect HIF-1 DNA binding were used to
examine the testicular HIF-1 DNA-binding ability.
The results of the HIF-1 DNA-binding ELISA demon-
strated binding of testicular HIF-1 to HRE sequences
contained in microwell plates (Figure 1). The HIF-1
DNA-binding activities in testes protein samples from
sham, 1 h I and 1h/4h I/R experiments were significantly
higher than in negative control samples, but there was
no significant difference in the binding activities between
experimental samples (ANOVA, p<0.05), indicating that
the normoxic and ischemic samples showed similar
levels of testicular HIF-1 DNA-binding activity.
Electrophoretic mobility shift experiments demonstrate
testicular HIF-1 binding
The HIF-1 EMSA experiments revealed binding of HIF-1
from cytoplasmic and nuclear extracts from the normoxic
testis to biotin-labelled HIF-1 oligonucleotides containing
a consensus HRE, demonstrating that testicular HIF-1 is
active and capable of binding the HIF HRE (Figure 2).
Supershift assays with two different polyclonal antibodies,
C19 and Y15, revealed corresponding shifts (Figure 3A).
Competition experiments using increasing concentrations
of unlabeled HIF-1 oligonucleotides containing the con-
sensus HRE demonstrated the specificity of HIF-1 HRE
binding by the testicular extracts (Figure 3B).
The EMSA results confirmed the HIF-1 DNA-binding
ELISA results, in that both nuclear and cytoplasmic
extracts from the testis demonstrated HIF-1 binding in
the EMSAs, and there were no quantitative differences
detected in HIF-1 binding between extracts from nor-
moxic testes, sham-treated testes and 1h ischemic testes
(Figure 4).
Mcl-1 protein is abundant in the testis and unaffected by
ischemia and ischemia/reperfusion
To understand the role of HIF-1 in the testis and mo-
lecular pathways involving HIF-1, we were interested in
identifying potential target genes for testicular HIF-1. In
silico analysis of testis genes containing the consensus
HRE (5’-RCGTG-3’) identified the induced myeloid
leukemia cell differentiation (Mcl-1) gene as a potential
HIF-1 target gene.
Immunoblot analysis of nuclear protein extracts was
performed to determine if Mcl-1 is present in the nor-
moxic and ischemic testes. Immunoblots probed with an
Mcl-1 primary antibody detected the large, primary
subunit of Mcl-1 (40 kDa) in nuclear extracts from
sham-treated and ischemic testis (Figure 5A). We were
particularly interested in this larger gene product because
Figure 1 Testicular HIF-1 displays DNA-binding activity by ELISA. Nuclear protein extracts from ischemic (I) testes, sham-treated (S) testes,
and testes subjected to ischemia-reperfusion (I/R) demonstrating in vitro binding to the HIF HRE in ELISA experiments. Absorbance readings were
quantitated as the fold increase over negative control values. COS-7 protein extracts were included as positive controls for HIF-1 DNA binding.
The HIF-1 binding in experimental samples was significantly higher than that in negative control samples (*ANOVA, p<0.05), but there were no
statistically significant differences in binding activity among the experimental samples.
Figure 2 Electrophoretic Mobility Shift Assays (EMSA) for testicular HIF-1 binding. The DNA-binding activity of testicular HIF-1 was
determined in EMSA experiments. (A) Results of positive control experiment using biotin-labelled oligonucleotides for Epstein-Barr nuclear
antigen (EBNA), a positive control protein extract for EBNA (Ext), competition with unlabeled EBNA oligonucleotides, and competition with non-
specific oligonucleotides for β-actin. (B) Representative EMSA results for cytoplasmic or nuclear (C) protein extracts from normoxic testes
incubated with biotin-labelled HIF-1 oligonucleotides containing the consensus HRE. Actin lanes contain a molar excess of unlabeled β-actin
oligonucleotides to demonstrate the specificity of protein binding to the HIF-1 oligonucleotides.
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Figure 3 EMSA supershift and competition assays for testicular
HIF-1 binding. (A) EMSA results when using cytoplasmic extracts of
testicular HIF-1 and the resulting supershifts demonstrated with C19
and Y15 polyclonal antibodies specific for HIF-1α. (B) Competition
experiments to determine HIF-1 EMSA binding specificity used
unlabeled HIF-1 HRE consensus oligonucleotides at increasing
concentrations to abrogate HIF-1 oligonucleotide binding by
testicular extracts.
Figure 4 HIF-1 from the normoxic and ischemic testes binds
the HIF-1 consensus HRE. Cytoplasmic and nuclear extracts of
testicular proteins from normoxic sham-treated (S) and 1 hour
ischemic (I) testes were subjected to EMSA to demonstrate HIF-1
binding. Testicular HIF-1 from ischemic and sham-treated testes
bound DNA equally.
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apoptosis. Quantitation of Mcl-1 normalized to ATF-2
as a percent of the level in sham control indicated no
significant difference in the amount of Mcl-1 protein
detected in normoxic and ischemic testis samples
(Figure 5B). A smaller, alternatively spliced isoform of
Mcl-1, which functions to promote apoptosis, was also
found to be present in the testis upon overexposure of
blots (see Figure 6) and its expression was unaffected by
ischemia (data not shown).Immunocytochemistry and immunoblot analyses reveal
that Mcl-1 is localized in leydig cells
Once we had determined that Mcl-1 is abundantly
expressed in the testis, it was necessary to determine if
Mcl-1, like testicular HIF-1, is also expressed by Leydig
cells. Spleen was used as a positive control because it is an
organ known to express high levels of Mcl-1 (Figure 7A
and B). Immunocytochemical analysis detected Mcl-1 pro-
tein in the normoxic testis and Mcl-1 was clearly localized
to Leydig cells (Figure 7D). Immunoreactivity for Mcl-1
was not observed in negative control sections incubated
without primary (Figure 7A and C).
Mcl-1 was also detected in protein extracts isolated from
cultured Leydig cells via immunoblot analysis (Figure 7).
We previously showed that Leydig cells cultured under 5%
or 21% oxygen exhibit down-regulated expression of HIF-1.
[12] Interestingly, Mcl-1 expression in Leydig cells cultured
under these same conditions also exhibited down-regulated
expression. Because we hypothesize that HIF-1 regulates
Mcl-1 expression through an HRE in the Mcl-1 promoter,
these results provide further support that HIF-1 may regu-
late Mcl-1 expression in the testis (Figure 6).Chromatin immunoprecipitation (ChIP) assays indicate
that Mcl-1 is a target for testicular HIF-1
ChIP assays were conducted to determine if testicular
HIF-1 binds the promoter of Mcl-1 as a HIF-1 target
gene in vivo. Control experiments demonstrated the ef-
fect of shearing time on the quality of chromatin
obtained and the specificity of the ChIP assay in pulling
down DNA-binding proteins and excluding non-specific,
DNA-binding protein complexes using β-actin as a
negative control (Figure 8A). Chromatin complexes pre-
cipitated with a HIF-1α antibody produced a PCR ampli-
con when using Mcl-1 primers that was not detectable in
PCR assays containing input DNA that was not immuno-
precipitated with the HIF-1α antibody (Figure 8B). DNA
sequence analysis confirmed that the amplified product
detected via PCR with the Mcl-1 primers amplified the
Mcl-1 promoter spanning the HRE consensus sequence
(data not shown).
Figure 5 Mcl-1 is abundantly expressed in the testis, and Mcl-1 levels do not change following ischemia or ischemia-reperfusion. (A)
Results of Mcl-1 immunoblot analysis of nuclear proteins isolated from experimentally-induced unilaterally ischemic testes (I) and sham-treated
testes (S). Aliquots containing 75-μg of nuclear proteins were analyzed from testes subjected to 1 h or 6 h of ischemia, and ischemia and
reperfusion (I/R) for 1h/4h. Mcl-1 was detected at ~40kDa. Extracts from the PC-12, Ramos and BJAB cell lines were used as positive controls for
detecting Mcl-1. Activating transcription factor-2 (ATF-2) was detected as a loading control as a protein that is constitutively expressed and is
unaffected by ischemia. (B) Histogram showing Mcl-1 quantitation normalized to ATF-2 as a percentage of the sham controls. No statistically
significant differences in the steady state levels of the Mcl-1 protein were observed between the ischemic and normoxic groups (ANOVA, p<0.05, n=3-5).
Palladino et al. Reproductive Biology and Endocrinology 2012, 10:104 Page 9 of 13
http://www.rbej.com/content/10/1/104Discussion
Recently, we demonstrated that HIF-1α is the predomin-
ant HIF subunit expressed in the rat testis and that Ley-
dig cells are the primary cell type producing HIF-1 in
the testis [12]. We also reported that HIF-1α appears to
be constitutively present in the normoxic rat testis and
is unaffected by ischemia and I/R. In most tissues, HIF-
1α is an oxygen-dependent subunit and it has been wellFigure 6 Mcl-1 is present in cultured rat Leydig cells.
Immunoblot analysis of Mc1-1 in cytoplasmic protein extracts from
whole, normoxic rat testis (75 μg of protein), and cytoplasmic
extracts from ~1 million freshly isolated rat Leydig cells (Fresh L.C.)
or Leydig cells cultured for 20 hours under either 5% or 21%
oxygen. The large (Mc1-1L) and small (Mcl-1S) subunits of Mcl-1 are
shown. The blot shown here was intentionally over-exposed to
reveal low but detectable levels of Mcl subunits in cultured Leydig
cells.established that the hypoxic up-regulation of HIF-1α
protein and its rapid degradation under normoxia are
controlled through changes in protein stability [22]. The
abundance of HIF-1 expressed by normoxic Leydig cells
suggests potentially novel roles for HIF-1 in the physi-
ology of the testis.
Investigators have reported normoxic expression of
HIF-1α in mesenchymal stem cells [23], cartilage [24],
mouse brain and kidney [25], rat kidney [26], and pul-
monary and vascular smooth muscle cells [27,28] among
other tissues. One goal of the present study was to de-
termine if rat testicular HIF-1 from normoxic and hyp-
oxic testes is capable of binding DNA. Our results from
an ELISA-based DNA-binding experiment and from
EMSA demonstrated that testicular HIF-1 from nor-
moxic and ischemic tissues bound DNA at equivalent
levels, suggesting that testicular HIF-1 is an active tran-
scription factor in both normoxic and ischemic testes.
Although we recognize that DNA binding in vitro does
not necessarily prove that there is transactivation of a
promoter by HIF-1 in vivo.
Initially, we became interested in studying testicular
HIF-1 because we thought that it might play a role in
oxygen homeostasis in the testis, particularly under con-
ditions of ischemia and ischemia-reperfusion, such as
during testicular torsion. Ischemia and ischemia-
Figure 7 Immunocytochemical localization of Mcl-1 in the normoxic testis. (A) Negative control section from rat spleen incubated with a
goat-anti-rabbit HRP secondary antibody in the absence of the Mcl-1 primary antibody (400×). (B) Positive control section from a spleen section
showing Mcl-1 immunoreactivity (400×). (C) Negative control section of normoxic testis incubated with goat-anti-rabbit HRP secondary antibody
in the absence of the Mcl-1 primary antibody (400×). (D) Normoxic testis section showing Mcl-1 immunoreactivity in Leydig cells indicated by
arrows (400×). The sections were counterstained with hematoxylin. Bar, 100 μm.
Figure 8 Chromatin immunoprecipitation enriches for testicular HIF-1/chromatin complexes bound to the Mcl-1 promoter.
(A) Representative example of a ChIP control experiment to determine the optimum shearing time and quality of shearing over time via
amplification of β-actin genomic DNA sequences in input DNA from normoxic rat testis. As a negative control, DNA was immunoprecipitated
with a β-actin polyclonal antibody for the purpose of determining the specificity of ChIP assays (because β-actin is not a classic DNA-binding
protein) and then subjected to PCR. (B) ChIP assays to detect HIF-1 binding in normoxic testis demonstrated complexes enriched for Mcl-1
promoter sequences when precipitated using a HIF-1α antibody (+) compared to input DNA that was not immunoprecipitated with the HIF-1α
antibody (−). Negative controls in which a nonspecific IgG antibody was used for immunoprecipitation revealed no amplification of Mcl-1
promoter sequences.
Palladino et al. Reproductive Biology and Endocrinology 2012, 10:104 Page 10 of 13
http://www.rbej.com/content/10/1/104
Palladino et al. Reproductive Biology and Endocrinology 2012, 10:104 Page 11 of 13
http://www.rbej.com/content/10/1/104reperfusion of the testis result in germ cell apoptosis.
However, after we localized HIF-1 to Leydig cells we
hypothesized that one role of HIF-1 may be to activate
antiapoptotic target genes to protect Leydig cells from
apoptosis during ischemia and ischemia-reperfusion.
HIF-1 may also play other important roles in Leydig cell
physiology. For example, in the mouse testis, HIF-1α
regulates the expression of the 3β-hydroxysteroid de-
hydrogenase type I (Hsd3b1) gene in Leydig cells [14],
and up-regulated expression of HIF-1α has been
reported in experimentally-induced varicoceles in the rat
testis [29].
An emerging body of research has also demonstrated
that HIF-1-mediated pathways are involved in inflamma-
tory responses [30,31]. Recent work in our laboratory
has shown that testicular HIF-1 expression is up-
regulated by LPS-induced inflammation of the testis (un-
published observations, Patel, D., Dugan, C., Karpodinis,
M, Fasano, G. M., and Palladino, M.A. Up-regulation of
testicular hypoxia-inducible factor-1α following E.coli
and P. aeruginosa lipopolysaccharide-induced inflamma-
tion. Manuscript under review).
For a variety of reasons, the testis has been described
as a hypoxic tissue [32]. Studies designed to measure the
physiological oxygen tension in the testis indicate that
testicular pO2 levels are likely low, bordering on hypoxia
[16,17]. As we have reported previously [12], the low
oxygen tension in this tissue under conditions that are
generally considered to correspond to normoxic physi-
ology is likely the reason that HIF-1 is highly expressed
in the “normoxic” testis and is apparently unregulated
by I and I/R, in contrast to what is observed in other tis-
sues. Therefore, the functional significance of constitu-
tive expression of testicular HIF-1α in the normoxic
testis is of significant interest to us.
Once we established that in rats testicular HIF-1 binds
DNA equally under normoxic and ischemic conditions,
we turned our attention to identifying potential HIF-1
target genes in the testis. In silico analysis of testis genes
containing a consensus hypoxia response element (HRE,
5’-RCGTG-3’) identified the induced myeloid cell
leukemia differentiation (Mcl-1) gene as a potential HIF-
1 target gene. Immunoblot analysis to detect MCL-1
demonstrated that MCL-1 protein is highly expressed in
the normoxic and ischemic testis and is localized to Ley-
dig cells, presenting a pattern that mimics the distribu-
tion of HIF-1.
Through ChIP assays using anti-HIF-1 antibodies we
isolated chromatin complexes enriched for Mcl-1 pro-
moter DNA sequences and sequence analysis confirmed
that the HIF-1 complexes contained the HRE of the
Mcl-1 promoter. Mcl-1 is member of the B-cell lymph-
oma family of anti-apoptotic proteins [33] and is an ac-
tive target in cancer research [34]. Examination of theantiapoptotic effects of HIF-1 in endothelial cells [35]
has shown that the antiapoptotic roles of HIF-1 are
mediated via regulating the expression of Mcl-1 [36]. Re-
cently, Iqbal et al. demonstrated that Mcl-1 expression is
up-regulated by platelet derived growth factor (PDGF) in
a HIF-1-dependent manner in prostate cancer cells and
that pharmacological inhibition of the PDGF receptor
decreases Mcl-1 levels and induces apoptosis in meta-
static prostate cancer cells [37].
Here, we propose that the co-localization of HIF-1 and
Mcl-1 observed in Leydig cells, showing a coordinated
pattern of expression, together with the results of our
experiments using a HIF-1 antibody in ChIP analysis,
which identified the HRE in the Mcl-1 promoter in HIF-
1-precipitated complexes, provides evidence that testicu-
lar HIF-1 binds to Mcl-1 as a target gene. We recognize
that these results alone do not definitively demonstrate a
functional or direct role for HIF-1 or Mcl-1 in the testis.
However, we previously reported that Leydig cells cul-
tured under 5% or 21% oxygen showed down-regulated
expression of HIF-1 [12]. In the current study, Mcl-1 ex-
pression in Leydig cells cultured under these same con-
ditions was also diminished, suggesting that HIF-1
expression correlates well with Mcl-1 expression in a
coordinated fashion, though we did not determine if an
increase in Leydig cell apoptosis resulted from down-
regulated expression of Mcl-1 in these in vitro
experiments.
Pharmacological studies are currently underway in our
laboratory to determine the physiological significance of
the inhibition of HIF-1 and/or Mcl-1 in Leydig cell biol-
ogy in normoxic and hypoxic testes. We are also investi-
gating the molecular mechanisms involved in stabilizing
testicular HIF-1 in the normal testis in vivo under condi-
tions that are presumed to be normoxic.
Conclusions
In conclusion, we have demonstrated that testicular
HIF-1 from normoxic and ischemic rat testes binds
DNA, suggesting potentially novel roles for HIF-1 and
Leydig cells in regulating the cellular and molecular
responses to oxygen in the testis. We have provided evi-
dence that Mcl-1 is a target gene of HIF-1. Further ex-
ploration of this interaction will be essential for
exploring cellular and molecular responses to ischemia
and hypoxia in the testis to advance our understanding
of the role of HIF-1 in Leydig cells and the pathophysio-
logic effects of hypoxia and other conditions affecting
the HIF-1 pathway in the testis.
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